Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 8/20 | 0.51 |
| ▸ | CTSB | P07858 | 3/20 | 0.50 |
| ▸ | DPP4 | P27487 | 3/20 | 0.43 |
| ▸ | FAP | Q12884 | 1/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
| ▸ | PLG | P00747 | 2/20 | 0.39 |
| ▸ | PLAT | P00750 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | VHL | P40337 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2194423 | 0.98 | CAPN1 (0.48) | CAPN1CTSBDPP4FAPDPP8 | |
| SCHEMBL2184762 | 0.98 | CAPN1 (0.48) | CAPN1CTSBDPP4FAPDPP8 | |
| SCHEMBL21519838 | 0.98 | CAPN1 (0.48) | CAPN1CTSBDPP4FAPDPP8 | |
| SCHEMBL29397226 | 0.90 | DPP4 (0.44) | CAPN1CTSBDPP4FAPDPP8 | |
| SCHEMBL30800860 | 0.88 | DPP4 (0.44) | CAPN1CTSBDPP4FAPDPP8 | |
| SCHEMBL29397117 | 0.87 | DPP4 (0.46) | CAPN1CTSBDPP4FAPDPP8 | |
| SCHEMBL30800861 | 0.87 | DPP4 (0.43) | CAPN1CTSBDPP4FAPDPP8 | |
| SCHEMBL29765255 | 0.86 | CAPN1 (0.47) | CAPN1CTSBDPP4FAPDPP8 | |
| SCHEMBL30852867 | 0.86 | CAPN1 (0.41) | CAPN1CTSBDPP4FAPDPP8 | |
| SCHEMBL15481300 | 0.85 | DPP4 (0.42) | CAPN1CTSBDPP4FAPDPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352405-B2 | GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis | SANOFI (FR) | 2022-06-07 | — | — | US | claimed |
| US-20260116928-A1 | COMPOSITIONS AND PARTICLES FOR PAYLOAD DELIVERY | THORNHILL THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260055154-A1 | LONG-ACTING DUAL-AGONIST COMPOUND | CHENGDU AODA BIOTECHNOLOGY CO LTD (CN) | 2026-02-26 | — | — | US | disclosed |
| US-20230183310-A1 | Polypeptide Compounds and Use Thereof in the Prevention or Treatment of Diabetes or Diabetic Complications | SHENZHEN TURIER BIOTECH CO., LTD (CN) | 2023-06-15 | — | — | US | disclosed |
| US-11504433-B2 | Cholix-derived carriers for oral delivery of heterologous payload | APPLIED MOLECULAR TRANSPORT INC. (US) | 2022-11-22 | — | — | US | disclosed |
| US-20220275029-A1 | COMPOSITIONS AND PARTICLES FOR PAYLOAD DELIVERY | THORNHILL THERAPEUTICS, INC. | 2022-09-01 | — | — | US | disclosed |
| US-11352405-B2 | GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis | SANOFI (FR) | 2022-06-07 | — | — | US | disclosed |
| US-11324833-B2 | Cholix-derived carriers for oral delivery of heterologous payload | APPLIED MOLECULAR TRANSPORT INC. (US) | 2022-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183310-A1 | Polypeptide Compounds and Use Thereof in the Prevention or Treatment of Diabetes or Diabetic Complications | IAPP, PNLIP, DPP4 | CAPN1 2127/4885CTSB 110/4885DPP4 3/4885 |
| US-11352405-B2 | GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis | GLP1R, GCGR, GIPR | CAPN1 4524/4885CTSB 1945/4885DPP4 26/4885 |
| US-20260055154-A1 | LONG-ACTING DUAL-AGONIST COMPOUND | GIPR, GLP1R, GCG | CAPN1 2622/4885CTSB 1792/4885DPP4 81/4885 |
| US-20260116928-A1 | COMPOSITIONS AND PARTICLES FOR PAYLOAD DELIVERY | SLC47A2, SLC47A1, SLC39A14 | CAPN1 769/4885CTSB 356/4885DPP4 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.